OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Shitara on Zolbetuximab Plus mFOLFOX6 in CLDN18.2+, HER2– Gastric/GEJ Adenocarcinoma

January 20th 2023

Kohei Shitara, MD, discusses the evaluation of the combination of zolbetuximab plus mFOLFOX6 in patients with CLDN18.2–positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.

Dr. Shroff on Results of the SWOG 1815 Trial in Advanced Biliary Tract Cancers

January 20th 2023

Rachna T. Shroff, MD, MS, discusses efficacy data from the phase 3 SWOG 1815 trial investigating nab-paclitaxel plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in newly diagnosed patients with advanced biliary tract cancers.

Dr. O’Shaughnessy on DESTINY-Breast02 and DESTINY-Breast03 in Metastatic HER2+ Breast Cancer

January 20th 2023

Joyce A. O’Shaughnessy, MD, discusses key data from the phase 3 DESTINY-Breast02 and DESTINY-Breast03 trials in metastatic HER2-positive breast cancer.

Dr. Harrison on the Investigation of Combination Strategies in Frontline RCC

January 20th 2023

Michael R. Harrison, MD, discusses several ongoing or upcoming studies that may change the treatment paradigm in renal cell carcinoma.

Dr. Strickler on the FDA Approval of Tucatinib Plus Trastuzumab in mCRC

January 19th 2023

John H. Strickler, MD, discusses the significance of the FDA approval of tucatinib plus trastuzumab in metastatic colorectal cancer.

Dr. Dhakal on the Evolution of Pertuzumab Regimens in HER2+ Breast Cancer

January 18th 2023

Ajay Dhakal, MBBS, discusses the two key trials supporting the use of pertuzumab as a standard-of-care regimen in HER2-positive breast cancer.

Dr. Morgans on the Current Treatment Landscape For mHSPC

January 18th 2023

Alicia Morgans, MD, MPH, discusses current androgen deprivation therapy combinations and the investigation of radiopharmaceutical combinations for metastatic hormone-sensitive prostate cancer.

Dr. Harrison on the Effect of IO-Related Toxicities on Treatment Selection in RCC

January 18th 2023

Michael R. Harrison, MD, discusses common toxicities associated with immuno-oncology–based combinations and their effects on treatment selection in renal cell carcinoma.

Dr. O'Shaughnessy on Key Results From the EMERALD Trial in HR+/HER2- Breast Cancer

January 18th 2023

Joyce A. O’Shaughnessy, MD, discusses key results from the phase 3 EMERALD trial of elacestrant, and the potential effects of the agent’s approval on the use of oral selective estrogen receptor degraders for hormone receptor–positive, HER2-negative breast cancer.

Dr. Bravo-Cordero on the Role of the Extracellular Matrix in Breast Cancer Dormancy

January 18th 2023

Jose Javier Bravo-Cordero, MD, discusses the role of extracellular matrix proteomics and disseminating tumor cells when regulating the tumor microenvironment to induce dormancy in breast cancer.

Dr. Wainberg on Optimal Frontline Treatment Strategies for Metastatic ESCC

January 17th 2023

Zev A. Wainberg, MD, discusses standard frontline treatment approaches for patients with metastatic esophageal squamous cell carcinoma and highlights data supporting the use of tislelizumab in combination with chemotherapy in ESCC.

Dr. Alldredge on Symptom Management in Ovarian Cancer During PARP Inhibitor Treatment

January 17th 2023

Jill Alldredge, MD, discusses the management of symptoms in patients with ovarian cancer during treatment with a PARP inhibitor.

Dr. Botta on the Diagnosis and Treatment of ESCC

January 17th 2023

Gregory Botta, MD, PhD, discusses the diagnosis and treatment of patients with esophageal squamous cell carcinoma.

Dr. Seetharamu on Individualized Care in SCLC

January 16th 2023

Nagashree Seetharamu, MD, MBBS, discusses interpreting the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology and deciding when to initiate hospice care in patients with small cell lung cancer.

Dr. Garcia on Future Expectations of Trials and Therapies in Myelofibrosis

January 16th 2023

Jacqueline S. Garcia, MD, discusses the future expectations of trials and therapies to improve outcomes in myelofibrosis.

Dr. Zhang on the EV-302 Trial in Metastatic Urothelial Cancer

January 16th 2023

Tian Zhang, MD, discusses the investigation of the combination of enfortumab vedotin plus pembrolizumab in the phase 3 EV-302 trial in the frontline setting for metastatic urothelial cancer.

Dr. Jacobs on the Continued Impact of the CAPTIVATE trial in CLL

January 16th 2023

Ryan Jacobs, MD, discusses the implications of next-line treatment strategies following long-term data of the phase 2 CAPTIVATE trial in chronic lymphocytic leukemia.

Dr. Dreyling on Key Efficacy Results From the TRIANGLE Study in MCL

January 16th 2023

Martin Dreyling, MD, discusses key efficacy results from the phase 3 TRIANGLE study in mantle cell lymphoma.

Dr. Hirsch on Diagnosing and Managing Metastatic SCLC

January 16th 2023

Fred R. Hirsch, MD, PhD, discusses the rarity of diagnosing small cell lung cancer early in the disease course, unmet needs in SCLC screening, the importance of ECOG performance score when considering patients for clinical trials, and factors influencing hospice care decisions in patients with SCLC.

Dr. Pavlick on the Benefit of Neoadjuvant Immunotherapy in Resectable Melanoma

January 16th 2023

Anna C. Pavlick, DO, discusses the potential benefit of neoadjuvant immunotherapy prior to surgical resection, according to results from the phase 2 SWOG S1801 trial.